Portland, ORNCT07408856Now EnrollingIRB Ready

Ductal Carcinoma in Situ Clinical Trial in Portland, OR

Access cutting-edge ductal carcinoma in situ treatment through this phase 1 clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by Providence Health & Services

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access ductal carcinoma in situ specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ductal carcinoma in situ treatment provided free

Apply for This Portland Location

Check if you qualify for this ductal carcinoma in situ clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Ductal Carcinoma in Situ Study in Portland

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Sponsor: Providence Health & Services

Who Can Participate

Inclusion Criteria

Male or female patients with DCIS or LCIS found on core biopsy.
Tumor types allowed: Biopsy-identified DCIS or LCIS comprising a single lesion ≥ 1 cm and ≤ 5 cm in size by imaging (mammogram or MRI or ultrasound (US)) without evidence of invasive disease on the biopsy and US negative for suspicious ipsilateral lymph nodes.
Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.
Laboratory values within 72 hours of Day 0:
WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
Hgb ≥ 10 g/dL
Platelets ≥ 100,000 K/µL
Creatinine Clearance (using Cockcroft-Gault) ≥ 60.
AST/ALT ≤ 2.5 x ULN
Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Negative pregnancy test for people of childbearing potential (bHCG urine or serum)
Patients and their partners who are capable of conceiving must agree to use effective methods of contraception (non-hormonal only) during the course of treatment and for 165 days after last dose of CAN1012.

Exclusion Criteria

Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/hyperthyroidism are not exclusionary.
Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known history of Hepatitis C virus (defined as HCV RNA) infection. Testing for Hepatitis B and Hepatitis C is not required unless mandated by local health authority.
Has a baseline electrocardiogram (ECG) with a prolonged QTc interval \> 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT07408856) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ductal Carcinoma in Situ Treatment Options in Portland, OR

If you're searching for ductal carcinoma in situ treatment options in Portland, OR, this clinical trial (NCT07408856) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced ductal carcinoma in situ specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ductal carcinoma in situ clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Portland, OR

See all ulcerative colitis clinical trials recruiting in Portland — not just this study.

Browse Ulcerative Colitis Trials in Portland →

Browse More Trials by Condition

Ulcerative Colitis TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR